drugset / Trial / NCT07454122
CD5CAR-NK Cells for Refractory Invasive Mold Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD). The study population consists of patients aged ≥18 years with refractory mold infections. The number of patients treated will be 10. This is a dose-escalation study including 3 cohorts.
Timeline
- Start
- 2026-05
- Primary completion
- 2029-05
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD5CAR-CBNK | Cell therapy | 1e+07 cells | — |
| Subject | CD5CAR-CBNK | Cell therapy | 2.5e+07 cells | — |
| Subject | CD5CAR-CBNK | Cell therapy | 5e+07 cells | — |